REFINE-Lung采用新型多臂随机试验设计以应对可能的免疫治疗过度治疗
越来越多证据提示晚期癌症部分免疫治疗给药方案可能导致过度治疗。本文讨论抗PD-1药物过度治疗问题并介绍REFINE-Lung(NCT05085028),一项英国多中心3期研究,采用新型多臂多阶段连续干预应答(MAMS-ROCI)设计确定帕博利珠单抗最佳给药频率。该设计或可形成跨癌种免疫治疗优化研究模板。
要点
- 晚期癌症部分免疫治疗给药方案可能导致过度治疗,需新方法识别并减少不必要治疗。
- 传统两臂非劣效设计在此背景下效率低,因需大量患者探索单一替代方案。
- REFINE-Lung采用MAMS-ROCI设计确定晚期非小细胞肺癌中帕博利珠单抗最佳给药频率。
核心结论
- REFINE-Lung与MAMS-ROCI设计或可促成改变临床实践的进展,并形成跨癌种免疫治疗优化研究模板。
- 该新型试验设计适用于许多需优化剂量、频率或疗程的新药或现有药物。
研究设计与样本
- REFINE-Lung(NCT05085028)为英国多中心3期研究,采用多臂多阶段连续干预应答(MAMS-ROCI)设计。
- 研究纳入晚期非小细胞肺癌患者,评估降低频率的帕博利珠单抗给药方案。
- 另有一项类似设计的篮式研究纳入肾癌和黑色素瘤患者。
主要发现
- 越来越多证据提示晚期癌症部分免疫治疗给药方案可能导致过度治疗。
- 传统两臂非劣效设计在此背景下效率低,因需大量患者探索单一替代方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increasing evidence suggests that some immunotherapy dosing regimens for patients with advanced cancer could result in overtreatment. Given the high costs of these agents, and important implications for quality of life and toxicity, new approaches are needed to identify and reduce unnecessary treatment. Conventional two-arm non-inferiority designs are inefficient in this context because they require large numbers of patients to explore a single alternative to the standard of care. Here, we discuss the potential problem of overtreatment with anti-PD-1 directed agents in general and introduce REFINE-Lung (NCT05085028), a UK multicentre phase 3 study of reduced frequency pembrolizumab in advanced non-small-cell lung cancer. REFINE-Lung uses a novel multi-arm multi-stage response over continuous interventions (MAMS-ROCI) design to determine the optimal dose frequency of pembrolizumab. Along with a similarly designed basket study of patients with renal cancer and melanoma, REFINE-Lung and the MAMS-ROCI design could contribute to practice-changing advances in patient care and form a template for future immunotherapy optimisation studies across cancer types and indications. This new trial design is applicable to many new or existing agents for which optimisation of dose, frequency, or duration of therapy is desirable.
引用
- Ghorani E, Quartagno M, Blackhall F, et al. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. Lancet Oncol. 2023. PMID: 37142383. doi:10.1016/S1470-2045(23)00095-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。